keyword
MENU ▼
Read by QxMD icon Read
search

Neurogenic overactive bladder

keyword
https://www.readbyqxmd.com/read/28716325/peripheral-and-sacral-neuromodulation-in-the-treatment-of-neurogenic-lower-urinary-tract-dysfunction
#1
REVIEW
Paholo G Barboglio Romo, Priyanka Gupta
Sacral and peripheral neuromodulation are minimally invasive surgical procedures that are third-line therapy options for the treatment of patients with idiopathic overactive bladder syndrome. There has been interest in their efficacy in the management of neurogenic lower urinary tract dysfunction (NLUTD). Contemporary data suggest promising outcomes for urinary and bowel symptoms in carefully selected patients with spinal cord injury and/or multiple sclerosis. This article reviews the current literature regarding urinary and bowel outcomes in patients with NLUTD and also discusses contemporary studies that suggest that treatment during particular stages of neurologic injury may prevent long-term urinary sequelae...
August 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/28716323/chronic-urinary-retention-in-multiple-sclerosis-patients-physiology-systematic-review-of-urodynamic-data-and-recommendations-for-care
#2
REVIEW
John T Stoffel
Many multiple sclerosis (MS) patients are affected by urinary retention. Common causes include neurogenic underactive bladder and/or bladder outlet obstruction from detrusor sphincter dyssynergia. Systemic review of contemporary MS urodynamic studies demonstrates that 53% of MS patients have detrusor overactivity, 43% have detrusor sphincter dyssynergia, and 12% have atonic bladder (12 studies, 1524 patients). There is no standard definition of MS-related urinary retention, but greater than 300 mL is a proposed threshold value for the condition based on literature review...
August 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/28714784/the-management-of-paediatric-neurogenic-bladder-an-approach-in-a-resource-poor-setting
#3
Patrick Opoku Manu Maison, John Lazarus
BACKGROUND: If untreated, paediatric neurogenic bladder can cause renal failure and urinary incontinence. It is usually caused by neural tube defects such as myelomeningocele. Children with a neurogenic bladder should be monitored from birth and management should aim to preserve renal function and achieve social continence. This article outlines the management options appropriate for these children in resource-poor settings. ASSESSMENT: In most low- and middle-income countries, a general lack of awareness of the neurological effects on the urinary tract results in late presentation, usually with urological complications even when spina bifida is diagnosed early...
July 17, 2017: Paediatrics and International Child Health
https://www.readbyqxmd.com/read/28712052/pharmacotherapy-for-pediatric-neurogenic-bladder
#4
REVIEW
Paweł Kroll
Neurogenic bladder (NB) is a nonspecific term that may describe conditions ranging from areflectic noncontractile bladder to detrusor overactivity. The most common cause of NB in children is the presence of dysraphic malformations. Urodynamic evaluations make it possible to describe bladder dysfunctions and to plan a therapeutic strategy for each patient. In a child with NB there are two major dangerous functional problems seen in urodynamic investigations: high intravesical pressure in the storage phase and high pressure during urination...
July 15, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28675645/adult-onset-nocturnal-enuresis-identifying-causes-cofactors-and-impact-on-quality-of-life
#5
Dominic Lee, Benjamin E Dillon, Gary E Lemack
OBJECTIVES: The objectives of the present study were: (i) Evaluate common co-pathologies associated with, and potentially contributing to adult onset Nocturnal enuresis (NE) in a tertiary referral population; and (ii) quantify its impact on QoL with validated questionnaires. METHODS: Following Institutional Review Board approval, patients with adult onset NE were reviewed with history, physical examination, urodynamic studies, questionnaires: Overactive bladder questionnaire short-form (OAB-qSF), Urogenital Distress Inventory (UDI-6), AUA symptom score (AUA-SS) and Patient Global Impression scale (PGIS)...
July 3, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28666061/conditional-neuromodulation-of-neurogenic-detrusor-overactivity-using-transrectal-stimulation-in-patients-with-spinal-cord-injury-a-proof-of-principle-study
#6
Sarah Louise Knight, Nuwani Edirisinghe, Brian Leaker, Judith Susser, Michael Duncan Craggs
AIMS: A proof of principle study of a novel wearable device to control neurogenic detrusor over-activity in eight male spinal cord injured subjects using conditional neuromodulation. METHODS: Transrectal stimulation was delivered through the device in response to simultaneously recorded external anal sphincter (EAS) contraction as a marker for neurogenic detrusor overactivity (NDO). The effect of conditional neuromodulation on bladder capacity and maximum detrusor pressure was investigated in addition to reliability of dyssynergic sphincter contraction as a marker for NDO...
June 30, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28645869/real-time-changes-in-brain-activity-during-sacral-neuromodulation-for-overactive-bladder
#7
Bradley C Gill, Javier Pizarro Berdichevsky, Pallab K Bhattacharyya, Thaddeus S Brink, Brian K Marks, Adrienne Quirouet, Sandip P Vasavada, Stephen E Jones, Howard B Goldman
PURPOSE: To use functional magnetic resonance imaging(fMRI) for identifying changes in brain activity during sacral neuromodulation(SNM) in women with overactive bladder(OAB) who were responsive to therapy. MATERIALS AND METHODS: Women with non-neurogenic refractory OAB who responded to SNM, had a stable program for at least 3 months, with no subsequent OAB treatment were recruited. Enrolled patients completed pre-fMRI validated symptom and quality of life instruments...
June 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28637786/the-role-of-capsaicin-sensitive-c-fiber-afferent-pathways-in-the-control-of-micturition-in-spinal-intact-and-spinal-cord-injured-mice
#8
Katsumi Kadekawa, Tsuyoshi Majima, Takahiro Shimizu, Naoki Wada, William C de Groat, Anthony J Kanai, Momokazu Goto, Mitsuharu Yoshiyama, Kimio Sugaya, Naoki Yoshimura
We examined bladder and urethral sphincter activity in mice with or without spinal cord injury (SCI) after C-fiber afferent desensitization induced by capsaicin pretreatment and changes in electrophysiological properties of mouse bladder afferent neurons 4 weeks after SCI. Female C57BL/6N mice were divided into 4 groups; (1) spinal intact (SI)-control, (2) SI-capsaicin pretreatment (Cap), (3) SCI-control and (4) SCI-Cap groups. Continuous cystometry and external urethral sphincter (EUS)-electromyogram (EMG) were conducted under an awake condition...
June 21, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28608967/urodynamic-effects-of-intravenous-and-intrathecal-administration-of-e-series-prostaglandin-1-receptor-antagonist-on-detrusor-overactivity-in-rats-with-spinal-cord-injury
#9
Naoki Wada, Katsumi Kadekawa, Tsuyoshi Majima, Takahiro Shimizu, Pradeep Tyagi, Hidehiro Kakizaki, Naoki Yoshimura
AIMS: We examined the effect of an E-series prostaglandin 1 (EP1) receptor antagonist on bladder activity using a rat model of spinal cord injury (SCI). METHODS: Female Sprague-Dawley rats were used. Six weeks after spinal cord transection, conscious-filling cystometry was performed. We evaluated the urodynamic parameters before and after intravenous (0.1 and 1.0 mg/kg) or intrathecal (0.1 and 1.0 µg) administration of SC51089, an EP1 antagonist. Spinal prostaglandin E2 (PGE2) concentration and EP1 receptor transcripts in the spinal cord and dorsal root ganglia (DRG) were measured by enzyme-linked immunosorbent assay and RT-PCR, respectively...
June 13, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28596838/botulinum-neurotoxins-serotypes-a-and-b-induce-paralysis-of-mouse-striated-and-smooth-muscles-with-different-potencies
#10
Jacquie Maignel-Ludop, Marion Huchet, Johannes Krupp
To address the scarcity of direct comparison of botulinum neurotoxin serotypes activity on smooth versus striatal muscle, we have studied the action of BoNT/A1 and BoNT/B1 on ex vivo preparations of both muscle types. We have set up and characterized a model of neurogenic contractions in the isolated mouse bladder, and used this model to explore the effects of the two serotypes on contractions evoked by electrical field stimulation. Both toxins were also tested in the mouse phrenic nerve hemidiaphragm assay, to compare their potency in smooth versus striated muscle...
February 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28546038/-pathophysiology-of-detrusor-underactivity-in-the-elderly
#11
J Kerdraon, B Peyronnet, X Gamé, B Fatton, R Haddad, C Hentzen, C Jeandel, P Mares, M Mezzadri, A-C Petit, G Robain, J-M Vetel, G Amarenco
AIM: The aim of this study was to review the evidence regarding the pathophysiology of detrusor underactivity in the elderly. METHODS: A literature review was conducted in July 2016 using the Medline/Pubmed database limiting the search to works in English or French. RESULTS: The prevalence of detrusor underactivity has been reported to range from 8% to 48% depending on the definition used and the age of the population studied. Current data suggest that aging may itself be a causative factor of detrusor underactivity through myogenic dysfunctions (ultrastructural degeneration of the detrusor muscle) and neurogenic dysfunctions (by degeneration of efferent but mostly afferent innervation mechanisms)...
May 22, 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/28540231/use-of-botulinum-toxin-for-voiding-dysfunction
#12
REVIEW
David Eldred-Evans, Prokar Dasgupta
The use of botulinum toxin A (BoNT-A) has expanded across a range of lower urinary tract conditions. This review provides an overview of the current indications for BoNT-A in the lower urinary tract and critically evaluates the published evidence within each area. The classic application of BoNT-A has been in the management of refractory neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). There is a large volume of high-quality evidence, including numerous randomized placebo-controlled trials, which demonstrate the efficacy of BoNT-A over a long follow-up period...
April 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28537692/long-term-response-of-different-botulinum-toxins-in-refractory-neurogenic-detrusor-overactivity-due-to-spinal-cord-injury
#13
Giuseppe Lombardi, Stefania Musco, Giovanni Bacci, Maria Celso, Valerio Bellio, Giulio Del Popolo
PURPOSE: To assess the response in spinal cord injured patients alternatively treated with different types and dosages of Botulinum neurotoxin type A (BoNT/A) over 15 years. MATERIAL AND METHODS: Patients who underwent first BoNT/A from 1999-2001 and practiced intermittent catheterization were included. Baseline 3-day bladder diary (BD) and urodynamics were collected. BoNT/A failure was defined when patients asked for re-injection ≤ 3 months post-treatment. Criteria for re-injection was at least one daily episode of urinary incontinence at BD...
May 23, 2017: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/28508889/influence-of-bladder-lithiasis-on-lower-urinary-tract-dynamics-in-patients-with-spinal-cord-injury
#14
M Vírseda-Chamorro, J Salinas-Casado, Á Barroso-Manso, P Gutiérrez-Martín, M E Fuertes
STUDY DESIGN: A prospective and a case-matched control study. OBJECTIVES: To study the lower urinary tract dysfunction associated with bladder lithiasis in patients with spinal cord injury (SCI). SETTING: Toledo (Spain). METHODS: We have carried out a urodynamic study in 30 patients with SCI with lithiasis in their bladder before and 3 months after bladder endoscopic lithotripsy. This second study was compared with the urodynamic findings of a different group of 30 patients with SCI, without a history of bladder lithiasis, paired with cases by gender and date of urodynamic study...
May 16, 2017: Spinal Cord
https://www.readbyqxmd.com/read/28486884/effect-of-intravesical-botulinum-toxin-injection-on-symptoms-of-autonomic-dysreflexia-in-a-patient-with-chronic-spinal-cord-injury-a-case-report
#15
Il-Young Jung, Kyo Ik Mo, Ja-Ho Leigh
CONTEXT: There are few treatment options for managing autonomic dysreflexia in patients with chronic spinal cord injury (SCI). According to some studies, intravesical botulinum toxin for SCI patients with autonomic dysreflexia has a preventive effect on symptoms of autonomic dysreflexia. However, the usefulness of an intravesical botulinum toxin injection has never been reported for autonomic dysreflexia in an adult patient with chronic cervical SCI, although there has been for one pediatric patient...
May 9, 2017: Journal of Spinal Cord Medicine
https://www.readbyqxmd.com/read/28431215/early-treatment-improves-urodynamic-prognosis-in-neurogenic-voiding-dysfunction-20-years-of-experience
#16
Lucia M Costa Monteiro, Glaura O Cruz, Juliana M Fontes, Eliane T R C Vieira, Eloá N Santos, Grace F Araújo, Eloane G Ramos
OBJECTIVE: To evaluate the association between early treatment and urodynamic improvement in pediatric and adolescent patients with neurogenic bladder. METHODOLOGY: Retrospective longitudinal and observational study (between 1990 and 2013) including patients with neurogenic bladder and myelomeningocele treated based on urodynamic results. The authors evaluated the urodynamic follow-up (bladder compliance and maximum bladder capacity and pressure) considering the first urodynamic improvement in two years as the outcome variable and early referral as the exposure variable, using a descriptive and multivariate analysis with logistic regression model...
April 19, 2017: Jornal de Pediatria
https://www.readbyqxmd.com/read/28431196/switch-to-abobotulinum-toxin-a-may-be-useful-in-the-treatment-of-neurogenic-detrusor-overactivity-when-intradetrusor-injections-of-onabotulinum-toxin-a-failed
#17
Florie Bottet, Benoit Peyronnet, Romain Boissier, Bénédicte Reiss, Jean G Previnaire, Andrea Manunta, Jacques Kerdraon, Alain Ruffion, Loïc Lenormand, Brigitte Perrouin Verbe, Sarah Gaillet, Xavier Gamé, Gilles Karsenty
AIMS: To assess the outcomes of switching to a different brand of botulinum toxin A (BTA, from Botox® to Dysport®) in case of failure of intradetrusor injections (IDI) of Botox® in the treatment of neurogenic detrusor overactivity (NDO). METHODS: The charts of all patients who underwent a switch to IDI of Dysport® after failure of an IDI of Botox® at six departments of neurourology were retrospectively reviewed. The main outcomes of interest were the bladder diary data and four urodynamic parameters: maximum cystometric capacity (MCC), maximum detrusor pressure (PDET max), and volume at first uninhibited detrusor contraction (UDC)...
April 21, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28403849/real-life-persistence-rate-with-antimuscarinic-treatment-in-patients-with-idiopathic-or-neurogenic-overactive-bladder-a-prospective-cohort-study-with-solifenacin
#18
Marloes J Tijnagel, Jeroen R Scheepe, Bertil F M Blok
BACKGROUND: Several studies have shown that the antimuscarinic treatment of overactive bladder is characterized by low long-term persistence rates. We have investigated the persistence of solifenacin in real life by means of telephonic interviews in a prospective cohort. We included both patients with idiopathic overactive bladder as well as neurogenic overactive bladder. METHODS: From June 2009 until July 2012 patients with idiopathic or neurogenic overactive bladder who were newly prescribed solifenacin were included...
April 13, 2017: BMC Urology
https://www.readbyqxmd.com/read/28394529/-comprehensive-pharmacologic-management-of-overactive-bladder
#19
G G Krivoborodov, E I Tur
Overactive bladder (OAB) is a common and bothersome condition manifested by urgency, frequent urination, significantly impairing patients quality of life. The article presents an overview of the evidence on pharmacotherapy of neurogenic and idiopathic OAB. Selective M3 receptor blockers have been shown to be the medications of choice in treating these patients. Many studies have shown that solifenacin 10 mg is a starting dose for patients with OAB. Mirabegron (Betmiga) is the only 3-adrenergic receptor agonist approved for primary treatment of OAB patients refractory to anticholinergics or have their side effects...
April 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28389505/onabotulinumtoxina-injections-in-detrusor-facilitate-self-catheterisation-in-a-patient-with-paraplegia-and-bladder-outlet-dyssynergia
#20
François Hervé, Annick Viaene, Karel Everaert
This case report describes the case of improvement of clean intermittent catheterisation procedures after each intradetrusor administration of onabotulinumtoxinA in a 45-year-old man with L1 paraplegia with neurogenic detrusor overactivity and bladder outlet dyssynergia.On three occasions, improvement on clean intermittent catheterisation procedures appeared 10 to 14 days after intradetrusor injections of onabotulinumtoxinA and lasted for 9 months. We hypothesise a possible influence of intravesical injections of onabotulinumtoxinA on the storage reflex...
April 6, 2017: BMJ Case Reports
keyword
keyword
9454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"